ID: ALA5196292

Max Phase: Preclinical

Molecular Formula: C25H22F3N3O3

Molecular Weight: 469.46

Representations

Canonical SMILES:  Cc1cc(NC(=O)c2c(O)nn3ccccc23)c(C(C)C)cc1Oc1ccc(C(F)(F)F)cc1

Standard InChI:  InChI=1S/C25H22F3N3O3/c1-14(2)18-13-21(34-17-9-7-16(8-10-17)25(26,27)28)15(3)12-19(18)29-23(32)22-20-6-4-5-11-31(20)30-24(22)33/h4-14H,1-3H3,(H,29,32)(H,30,33)

Standard InChI Key:  FDUIIKFVYLTYJA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 469.46

Molecular Weight (Monoisotopic): 469.1613

AlogP: 6.54

#Rotatable Bonds: 5

Polar Surface Area: 75.86

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 6.06

CX Basic pKa: 0.02

CX LogP: 7.02

CX LogD: 5.80

Aromatic Rings: 4

Heavy Atoms: 34

QED Weighted: 0.35

Np Likeness Score: -1.18

References

1. Sainas S, Giorgis M, Circosta P, Poli G, Alberti M, Passoni A, Gaidano V, Pippione AC, Vitale N, Bonanni D, Rolando B, Cignetti A, Ramondetti C, Lanno A, Ferraris DM, Canepa B, Buccinnà B, Piccinini M, Rizzi M, Saglio G, Al-Karadaghi S, Boschi D, Miggiano R, Tuccinardi T, Lolli ML..  (2022)  Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety.,  65  (19.0): [PMID:36162075] [10.1021/acs.jmedchem.2c00496]

Source

Source(1):

• Scientific Literature